Prothena Corp. (NASDAQ:PRTA)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a research note issued on Monday. They currently have a $77.00 target price on the stock. Wedbush’s price objective would suggest a potential upside of 24.19% from the company’s previous close.
Several other analysts also recently weighed in on PRTA. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Prothena Corp. in a research note on Friday, June 10th. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Prothena Corp. in a research note on Friday, June 10th. Finally, Barclays PLC lifted their target price on Prothena Corp. from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, August 4th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $76.80.
Prothena Corp. (NASDAQ:PRTA) traded down 0.86% during mid-day trading on Monday, hitting $62.00. The company had a trading volume of 286,710 shares. The company’s 50 day moving average price is $55.38 and its 200-day moving average price is $46.87. The company’s market cap is $2.13 billion. Prothena Corp. has a one year low of $28.20 and a one year high of $76.42.
Prothena Corp. (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 2nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.91) by $0.27. Prothena Corp. had a negative net margin of 8,628.11% and a negative return on equity of 28.15%. The company had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.39 million. The business’s quarterly revenue was up 22.2% on a year-over-year basis. Equities research analysts anticipate that Prothena Corp. will post ($4.25) EPS for the current fiscal year.
In other news, insider Karin L. Walker sold 12,000 shares of the business’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $61.10, for a total value of $733,200.00. Following the sale, the insider now owns 7,000 shares of the company’s stock, valued at approximately $427,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Arthur W. Homan sold 3,125 shares of the business’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $52.16, for a total value of $163,000.00. Following the completion of the sale, the insider now directly owns 3,125 shares in the company, valued at approximately $163,000. The disclosure for this sale can be found here. 3.70% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of the company. TIAA CREF Investment Management LLC increased its stake in Prothena Corp. by 5.6% in the first quarter. TIAA CREF Investment Management LLC now owns 162,870 shares of the company’s stock worth $6,704,000 after buying an additional 8,600 shares in the last quarter. BlackRock Inc. boosted its position in shares of Prothena Corp. by 197.8% in the first quarter. BlackRock Inc. now owns 2,656 shares of the company’s stock worth $110,000 after buying an additional 1,764 shares during the last quarter. BlackRock Group LTD boosted its position in shares of Prothena Corp. by 23.1% in the first quarter. BlackRock Group LTD now owns 19,094 shares of the company’s stock worth $785,000 after buying an additional 3,577 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of Prothena Corp. by 10.0% in the first quarter. BlackRock Fund Advisors now owns 1,248,919 shares of the company’s stock worth $51,406,000 after buying an additional 113,332 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Prothena Corp. by 9.8% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 846,698 shares of the company’s stock worth $34,850,000 after buying an additional 75,385 shares during the last quarter.
Prothena Corp. Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
Receive News & Ratings for Prothena Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corp. and related companies with MarketBeat.com's FREE daily email newsletter.